Allink Biotherapeutics Raises $47M to Advance Two ADC Programs in Global Phase I Trials
核心洞察
Allink Biotherapeutics (搜索) completed $47 million Series A extension rounds led by Legend Capital (搜索) and Meituan Long-Z Investment (搜索) to advance clinical development programs.
The company's lead program ALK201, a potential first-in-class FGFR2b (搜索)-targeted ADC, has demonstrated encouraging efficacy signals across multiple tumor types with favorable safety profile.
ALK202, an EGFR (搜索)/cMET (搜索) bispecific ADC, shows preliminary support as a cornerstone therapy in non-small cell lung cancer (搜索) with expansion into broader biomarker-defined tumor populations.
Shanghai-based clinical-stage biotechnology company Allink Biotherapeutics (搜索) has successfully completed extension rounds of its Series A financing, raising $47 million to advance two differentiated antibody-drug conjugate (ADC) programs currently in global Phase I clinical trials. The extension rounds were led by existing supporter Legend Capital (搜索) and new investor Meituan Long-Z Investment (搜索), with participation from prominent returning and new investors including Lanchi Ventures, Yuanbio Venture Capital, 5Y Capital, Lapam Capital, and Runzhang Venture Capital.
Lead ADC Programs Show Clinical Promise
The company's flagship program, ALK201, represents a potential first- and best-in-class FGFR2b (搜索)-targeted ADC that has demonstrated encouraging efficacy signals across multiple tumor types with a favorable safety profile. This clinical performance supports the development of ALK201 as a backbone therapy for FGFR2b-overexpressing solid tumors (搜索), positioning it for broad therapeutic applications.
In parallel development, early clinical data for ALK202 have provided preliminary support for the EGFR (搜索)/cMET (搜索) bispecific ADC's potential as a cornerstone therapy in non-small cell lung cancer (搜索). The program is being expanded into clinical evaluation across a broader range of biomarker-defined tumor types and patient populations, reflecting the company's strategy to maximize therapeutic reach.
Biomarker-Guided Development Strategy
AllinkBio has implemented a biomarker-guided strategy for both lead clinical assets, designed to demonstrate efficacy across a broad spectrum of solid tumors (搜索). In the near term, the company plans to initiate combination therapy studies to further explore the therapeutic potential of both ALK201 and ALK202 in broader front-line patient populations. These initiatives are intended to accelerate both candidates toward pivotal trial readiness while establishing differentiated profiles in their respective target indications.
Platform Expansion Beyond ADCs
Expanding beyond its ADC technology, AllinkBio is establishing a proprietary masked T-cell engager (TCE) platform to evolve the application of TCEs for solid tumors (搜索). In the immunology space, the company is advancing a portfolio of first-in-class bi- and multi-specific antibody drug candidates. These programs are anchored in rational biology design and aim to deliver next-generation solutions for patient populations underserved by current standards of care.
Rapid Clinical Advancement
Founded in 2023, AllinkBio has rapidly advanced two ADC candidates into global Phase I trials by combining platform capabilities with strong R&D efficiency. The company plans to continue expanding its pipeline across oncology and immunology applications.
"We sincerely appreciate the decisive and continued support from our investors within such a short timeframe. With this support, we are moving forward with a clear clinical roadmap to accelerate our lead programs. Beyond the two leading programs, our discovery engine is fully activated, poised to deliver new wave of innovative drug candidates that will unlock further value in the foreseeable future," said Hui Feng, Ph.D., Founder and Chief Executive Officer of AllinkBio.
Tan Hong, Managing Director at Legend Capital (搜索), expressed confidence in the investment: "Our continued support is rooted in our confidence in the AllinkBio team's efficient execution and their robust development strategy. The rapid clinical advancement of their two competitive lead assets is already serving as a strong validation of the company's ADC platform and presenting significant value. We look forward to the near-term clinical readouts and seeing more innovative programs emerge from their discovery platforms."